An update from Palm Springs – Huntington’s disease Therapeutics Conference 2019
CHDI’s Huntington’s disease Therapeutics Conference 2019 has taken place and they have sent out an update from Palm Springs discussing all topics covered this year. The video update definitely confirms that we are living in exciting times in Huntington’s disease drug development!
The Roche ASO Phase 3 trial is now active and sites in Europe have recently begun to recruit, the use of wearable technology such as smartwatches and phones, are now being used to track movement and mood in clinical research and there are many other approaches aiming to lower huntingtin that are now approaching clinical trial. Plus, the recent genome-wide association studies have unearthed a very promising new area for Huntington’s therapeutics, and the family perspective is being incorporated into research and trial design as never before.
Watch the video below to learn more about what was discussed at the conference and the progression of current trials and research.
CHDI’s Huntington’s disease Therapeutics Conference 2019 has taken place and they have sent out an update from Palm Springs discussing all topics covered this year. The video update definitely confirms that we are living in exciting times in Huntington’s disease drug development!
The Roche ASO Phase 3 trial is now active and sites in Europe have recently begun to recruit, the use of wearable technology such as smartwatches and phones, are now being used to track movement and mood in clinical research and there are many other approaches aiming to lower huntingtin that are now approaching clinical trial. Plus, the recent genome-wide association studies have unearthed a very promising new area for Huntington’s therapeutics, and the family perspective is being incorporated into research and trial design as never before.
Watch the video below to learn more about what was discussed at the conference and the progression of current trials and research.